Maple Leaf Foods will close two of its three U.S. plant protein manufacturing sites by the fourth quarter of 2027, consolidating American production of the category at its Indianapolis Plant Protein Centre of Excellence.

The Toronto-based meat and protein producer confirmed that its Seattle, Washington, and Turners Falls, Massachusetts, operations will wind down over the coming quarters, with manufacturing volume transferred to the Indiana facility. The company did not disclose headcount figures for the affected plants or a timeline for individual line shutdowns within the multi-year wind-down window.\n The move concentrates U.S. output for Maple Leaf's plant-based portfolio — built around the Greenleaf Foods brand family — at a single site designed as a dedicated hub for the segment. The Indianapolis facility, which Maple Leaf has positioned as its Plant Protein Centre of Excellence, absorbs the production previously split across the three locations.

The consolidation signals a continued cost-discipline phase for the plant protein category, which drew heavy capital investment during the 2019–2021 alternative-protein boom but has since faced softer retail demand and persistent margin pressure. For a processor, running parallel underutilized lines across three states carries fixed costs — labor, energy, logistics, maintenance — that a single optimized site can reduce.

The wind-down schedule through Q4 2027 gives suppliers, contract carriers, and the affected workforces in Washington and Massachusetts a multi-year adjustment window rather than an abrupt exit. Turners Falls, in western Massachusetts's Pioneer Valley, and the Seattle operation both sit in regions where food-manufacturing employment ties into local industrial labor pools; state workforce agencies will typically engage on retraining and placement as closure dates firm up.

For Maple Leaf, the decision fits a broader pattern among diversified protein companies of rationalizing plant-based capacity to match actual volumes rather than the growth curves projected at the category's peak. Co-packing customers and foodservice buyers sourcing from the Seattle or Turners Falls sites will need to transition supply agreements to Indianapolis-sourced product ahead of the 2027 deadline, a shift that carries reformulation and logistics lead-time considerations even where product specifications carry over.

The company framed the Indianapolis centre as the platform for its U.S. plant protein business going forward. Whether the consolidation restores segment-level profitability will depend on utilization rates at the single site and on whether retail and foodservice demand for plant-based protein stabilizes — questions that Maple Leaf's next several reporting periods should begin to answer.